Monomethyl auristatin E(MMAE) powder

AASraw is with synthesis and production ability from gram to mass order of Monomethyl auristatin E(MMAE) powder (474645-27-7) , under CGMP regulation and trackable quality control system.

Monomethyl auristatin E(MMAE) powder is a very potent antimitotic agent that inhibits cell division by blocking the polymerisation of tubulin.The family of auristatins are synthetic analogues of the antineoplastic natural product Dolastatin 10,  ultrapotent cytotoxic microtubule inhibitors that are clinically used as payloads in antibody-drug conjugates. Monomethyl auristatin E or MMAE is 100-1000 times more potent than doxorubicin (Adriamycin/Rubex) and cannot be used as a drug itself..

Product Description

 

Monomethyl auristatin E(MMAE) powder video

 

 


 

I.Monomethyl auristatin E(MMAE) powder basic Characters:

 

Name: Monomethyl auristatin E(MMAE) powder
CAS: 474645-27-7
Molecular Formula: C39H67N5O7
Molecular Weight: 717.97858
Melt Point: 238-240°C
Storage Temp: Store in original container,between 36 to 46 degrees F
Color: White powder

 


 

II. Monomethyl auristatin E powder as antimitotic agent

 

1. Names:

Brentuximab vedotin, MMAE powder

 

2. Monomethyl auristatin E powder Usage:

• Adults
Monotherapy, 1.8 mg/kg (not to exceed 180 mg/dose) IV every 3 weeks; in combination with chemotherapy, 1.2 mg/kg (not to exceed 120 mg/dose) IV every 2 weeks.

• Geriatric
Monotherapy, 1.8 mg/kg (not to exceed 180 mg/dose) IV every 3 weeks; in combination with chemotherapy, 1.2 mg/kg (not to exceed 120 mg/dose) IV every 2 weeks.

Monomethyl auristatin E powder (MMAE powder, vedotin) is a very potent antimitotic agent that inhibits cell division by blocking the polymerisation of tubulin.The family of auristatins are synthetic analogues of the antineoplastic natural product Dolastatin 10, ultrapotent cytotoxic microtubule inhibitors that are clinically used as payloads in antibody-drug conjugates. Monomethyl auristatin E powder or MMAE powder is 100-1000 times more potent than doxorubicin (Adriamycin/Rubex) and cannot be used as a drug itself. However, as part of an antibody-drug conjugate or ADC, MMAE powder is linked to a monoclonal antibody (mAb) that recognizes a specific marker expression in cancer cells and directs MMAE powder to a specific, targeted cancer cell.

The linker linking MMAE powder to the monoclonal antibody is stable in extracellular fluid, but is cleaved by cathepsin once the antibody-drug-conjugate has bound to the targeted cancer cell antigen and entered the cancer cell, after which the ADC releases the toxic MMAE powder and activates the potent anti-mitotic mechanism. Antibody-drug conjugates enhance the antitumor effects of antibodies and reduce adverse systemic effects of highly potent cytotoxic agents.

 

3.Warning on Monomethyl auristatin E powder

 

• Pneumonitis, pulmonary disease, respiratory distress syndrome
Severe noninfectious pulmonary toxicity (e.g., pneumonitis, interstitial pulmonary disease, acute respiratory distress syndrome) has been reported with brentuximab therapy; some cases were fatal. Monitor patients for signs and symptoms of pulmonary toxicity such as cough and dyspnea. Evaluate patients who develop new or worsening pulmonary symptoms; hold brentuximab until symptoms improve. The concomitant use of brentuximab with bleomycin-containing chemotherapy (off-label), such as ABVD (adriamycin, bleomycin, vinblastine, dacarbazine), is contraindicated due to an increased risk of noninfectious pulmonary toxicity. Interstitial infiltration and/or inflammation (found on chest X-ray or computed tomographic imaging) occurred more often in Hodgkin lymphoma patients who received brentuximab plus ABVD in a clinical trial compared with historical control patients who received ABVD alone. Most cases resolved following corticosteroid treatment.

Peripheral neuropathy
Peripheral neuropathy, primarily sensory neuropathy, has been reported with brentuximab vedotin therapy; peripheral neuropathy is cumulative. Monitor patients for symptoms of neuropathy (e.g., hypoesthesia, hyperesthesia, paresthesia, discomfort, burning sensation, neuropathic pain, or weakness). Therapy interruption, dosage reduction, or discontinuation may be necessary in patients who develop new or worsening peripheral neuropathy.

• Anemia, geriatric, neutropenia, thrombocytopenia
Severe hematologic toxicities (e.g., anemia, thrombocytopenia, neutropenia) and fatal and serious cases of febrile neutropenia have been reported with brentuximab vedotin therapy; neutropenia may be prolonged (lasting 1 week or longer). Geriatric patients aged 65 years and older with Hodgkin lymphoma who received brentuximab vedotin in combination with chemotherapy experienced higher rates of febrile neutropenia compared with younger patients. Obtain complete blood counts prior to each brentuximab dose and more frequently if grade 3 or 4 neutropenia occurs; monitor all patients for fever. Therapy interruption, dosage reduction, or discontinuation may be necessary in patients who develop grade 3 or 4 neutropenia; consider the addition of prophylactic granulocyte-colony stimulating factor (G-CSF) with subsequent doses. Administer G-CSF starting with cycle 1 in patients receiving brentuximab vedotin in combination with chemotherapy.

• Tumor lysis syndrome (TLS)
Tumor lysis syndrome (TLS) has been reported in patients who received brentuximab vedotin. Patients with rapidly proliferating tumors and/or a high tumor burden may have an increased risk of developing TLS. Monitor patients for signs of TLS (e.g., serum electrolytes, uric acid, serum creatinine) prior to and during therapy; institute appropriate prophylactic and treatment (e.g., hydration, uric acid lowering therapy) as necessary.

• Progressive multifocal leukoencephalopathy
Fatal cases of progressive multifocal leukoencephalopathy (PML), caused by the John Cunningham virus (JC virus), have been reported with brentuximab therapy; some cases occurred within the first 3 months of starting therapy. Patients with prior immunosuppressive therapies or immunosuppressive disease may be at increased risk of JC virus infection and PML. Evaluate patients who develop new neurological, cognitive, or behavioral signs and symptoms such as changes in mood or behavior; confusion; memory impairment; changes in vision, speech, or walking; and/or decreased strength or weakness on one side of the body. Hold therapy if PML is suspected; discontinue brentuximab in patients with confirmed PML.

• Renal impairment
Avoid the use of brentuximab vedotin in patients with severe renal impairment (creatinine clearance (CrCl) less than 30 mL/min). The incidence of grade 3 or higher adverse events and death was higher in patients with severe renal impairment compared with patients with normal renal function (CrCl greater than 80 mL/min) in a small, single-dose pharmacokinetic study.

• Hepatic disease
Avoid the use of brentuximab vedotin in patients with moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic disease/impairment; a reduced starting dose is recommended in patients with mild hepatic impairment (Child-Pugh A). The incidence of grade 3 or higher adverse events and death was higher in patients with moderate or severe hepatic impairment compared with patients with normal hepatic function in a small, single-dose pharmacokinetic study. Hepatotoxicity (e.g., hepatocellular injury, elevated hepatic enzymes, and hyperbilirubinemia) has been reported with brentuximab vedotin therapy. Some cases occurred after the first dose or upon a drug rechallenge; hepatotoxicity-related death has been reported. Monitor liver function tests (LFTs), including bilirubin, before and during therapy. Therapy interruption, dosage reduction, or discontinuation may be necessary in patients who develop new, worsening, or recurrent hepatotoxicity. Patients with pre-existing hepatic disease or elevated LFTs at baseline and patients who are receiving concomitant medications may be at increased risk for developing hepatotoxicity.
• Infection, sepsis
Opportunistic infections and other serious infections, including pneumonia, bacteremia, and sepsis (some cases fatal), have been reported with brentuximab vedotin therapy. Closely monitor patients during treatment for signs and symptoms of bacterial, fungal, or viral infection.

• Infusion-related reactions
Infusion-related reactions including anaphylaxis have been reported with brentuximab vedotin therapy; therefore, monitor patients close for symptoms of a reaction during the brentuximab infusion. Immediately and permanently discontinue therapy if anaphylaxis occurs. Stop the infusion and institute appropriate medical management in patients who develop an infusion-related reaction. Premedicate (e.g., acetaminophen, antihistamine, and/or corticosteroid) prior to subsequent infusions in patients who have previously experienced an infusion-related reaction.

• Colitis, GI bleeding, GI disease, GI obstruction, GI perforation, ileus, peptic ulcer disease
Serious gastrointestinal (GI) complications including GI perforation, GI bleeding, GI erosion, peptic ulcer disease, GI obstruction, neutropenic colitis, enterocolitis, and ileus have been reported with brentuximab vedotin therapy; some cases resulted in death. Promptly evaluate and treat GI complications in patients who develop new or worsening GI symptoms. Use brentuximab with caution in patients with a history of GI disease. Patients who have a history of lymphoma with GI involvement may be at increased risk of GI perforation.

• Pregnancy
Brentuximab vedotin may cause fetal harm if administered during pregnancy based on its mechanism of action and data from animal studies. Females of reproductive potential should be advised to avoid becoming pregnant while receiving brentuximab. If a woman becomes pregnant while taking this drug, she should be apprised of the potential hazard to the fetus. In animal studies, embryo-fetal toxicities including congenital malformations were observed at brentuximab doses that resulted in maternal exposures that were similar to human exposures at the recommended dose.

• Contraception requirements, infertility, male-mediated teratogenicity, pregnancy testing, reproductive risk
Counsel patients about the reproductive risk and contraception requirements during brentuximab vedotin treatment. Pregnancy testing should be performed prior to starting brentuximab in female patients of reproductive potential. These patients should use effective contraception and avoid pregnancy during and for at least 6 months after brentuximab therapy. Women who become pregnant while receiving brentuximab should be apprised of the potential hazard to the fetus. Additionally, male patients with a female partner of reproductive potential should use effective contraception during therapy and for at least 6 months after therapy due to the risk of male-mediated teratogenicity. Based on animal studies, brentuximab may cause infertility in males.

• Breast-feeding
No information is available regarding the presence of brentuximab vedotin in human milk, the effects on the breastfed infant, or the effects on milk production. Due to the potential for serious adverse reactions in the nursing infant (e.g., cytopenias and neurologic or gastrointestinal toxicities), breast-feeding is not recommended during brentuximab therapy. Consider the benefits of breast-feeding, the risk of potential infant drug exposure, and the risk of an untreated or inadequately treated condition. If a breast-feeding infant experiences an adverse effect related to a maternally administered drug, healthcare providers are encouraged to report the adverse effect to the FDA.

 

4.Further instructions:

Monomethyl auristatin E powder (MMAE powder) is efficiently released from SGN-35 within CD30+ cancer cells and, due to its membrane permeability, is able to exert cytotoxic activity on bystander cells. MMAE powder sensitizes colorectal and pancreatic cancer cells to IR in a schedule and dose dependent manner correlating with mitotic arrest. Radiosensitization is evidenced by decreased clonogenic survival and increased DNA double strand breaks in irradiated cells.

 

5. Monomethyl auristatin E Raw Powder:

Min order 10grams.
The inquiry on normal quantity(Within 1kg) can be sent out in 12 hours after payment.
For larger order(Within 1kg)can be sent out in 3 workingdays after payment.

 

6. Monomethyl auristatin E  Raw Powder Recipes:

To inquiry our Customer Representitive(CSR) for details, for your reference.

 

7. Monomethyl auristatin E powder Marketing:

To be provided in the coming future.

 


 

III. Monomethyl auristatin E powder HNMR

 

We are monomethyl auristatin e powder supplie,MMAE powder for sale,Monomethyl auristatin E(MMAE) powder (474645-27-7) ≥98% | AASraw

 


 

IV. How to buy Monomethyl auristatin E powder; buy MMAE powder from AASraw?

 

1.To contact us by our email inquiry system,or online skypecustomer service representative(CSR).
2.To provide us your inquired quantity and address.
3.Our CSR will provide you the quotation, payment term, tracking number, delivery ways and estimated arrival date(ETA).
4.Payment done and the goods will be sent out in 12 hours(For order within 10kg).
5.Goods received and give comments.

 


 

Guess your favorite product blog:

 

 How I Sibutramine powder and How You Can Too How to take Lorcaserin powder correctly  Testosterone cypionate raw powder:Everything you should know about the amazing steroids!!!

 


 

More detail about relevant products,welcome to click here.


=

Reviews

There are no reviews yet.

Be the first to review “Monomethyl auristatin E(MMAE) powder”

Your email address will not be published. Required fields are marked *

Captcha *